Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 291

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 291
---
 stated, all references to “DiamiR,” and similar designations in this section refer to DiamiR Biosciences Corp, a Delaware corporation, and its wholly -owned subsidiary DiamiR, LLC a private Delaware limited liability company. Overview DiamiR Biosciences Corp. (“DiamiR”) is a molecular diagnostic company focused on developing minimally invasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer’s, Parkinson’s, other neurodegenerative diseases, and cancer. The proprietary technology developed at DiamiR is based on quantitative analysis of circulating organ -enrichedmicroRNAs in plasma. Short -termobjectives of DiamiR include the development of Lab -Developedtests (LDTs) under CLIA guidelines based on the identified miRNA expression signatures. The tests will be used for screening, patient stratification, as well as disease and treatment monitoring. DiamiR was incorporated in Delaware on June 16, 2014, and primarily operates through its wholly -ownedsubsidiary, DiamiR, LLC, which was incorporated as a limited liability company in Delaware on September 17, 2009. In October 2014, DiamiR entered into a Share Exchange Agreement with DiamiR, LLC, pursuant to which DiamiR acquired 100% of the issued and outstanding units of DiamiR, LLC in exchange for 4,282,000shares (100%) of DiamiR’s common stock (the “Share Exchange”), and DiamiR, LLC became a wholly -ownedsubsidiary of DiamiR. The Share Exchange was recognized as a combination of entities under common control as both DiamiR, LLC and DiamiR have been controlled before and after the transaction by the same shareholders. DiamiR has incurred net losses in each year since its inception, including net losses of $614,405 and $1,318,431 for the years ended May 31, 2024 and 2023, respectively, and $493,710 for the nine months ended February 28, 2025. At February 28, 2025, DiamiR had an accumulated deficit of $5,573,046, primarily due to operating expenses. DiamiR has devoted most of its financial resources to conducting studies on analysis of circulating organ -enrichedmiRNA biomarkers and building its patent portfolio. DiamiR has not completed development of any product candidate and has therefore not generated any revenues from product sales